Quarterly ResultAug 6, 2026, 08:53 AM
CG Oncology Q2 Net Loss $(79.1)M; Revenue $1.16M
AI Summary
CG Oncology reported a net loss of $79.1 million for Q2 2026, an increase from $41.4 million in Q2 2025, and a net loss of $139.3 million for the six months ended June 30, 2026. Total revenues for Q2 2026 were $1.16 million, up from zero in the prior year, and $2.24 million for the six-month period. The company maintained a strong liquidity position with $1.03 billion in cash, cash equivalents, and marketable securities. A significant legal proceeding against ANI Pharmaceuticals was resolved in the company's favor, eliminating future royalty obligations and damages.
Key Highlights
- Q2 2026 net loss increased to $(79.1) million from $(41.4) million in Q2 2025.
- Total revenues for Q2 2026 were $1.16 million, up from $0 in Q2 2025.
- Six-month net loss was $(139.3) million, compared to $(75.9) million in 2025.
- Cash, cash equivalents, and marketable securities totaled $1.03 billion as of June 30, 2026.
- Net cash used in operating activities for six months was $(103.4) million.
- Received $391.55 million from follow-on public offerings in the six months.
- Legal dispute with ANI Pharmaceuticals resolved in company's favor, eliminating future royalties.
- Research and development expenses increased to $54.7 million in Q2 2026.
Price Impact
More from CGON